HRP20110178T1 - Kinuklidinski derivati (hetero) arilcikloheptankarboksilne kiseline kao antagonisti muskarinskog receptora - Google Patents

Kinuklidinski derivati (hetero) arilcikloheptankarboksilne kiseline kao antagonisti muskarinskog receptora Download PDF

Info

Publication number
HRP20110178T1
HRP20110178T1 HR20110178T HRP20110178T HRP20110178T1 HR P20110178 T1 HRP20110178 T1 HR P20110178T1 HR 20110178 T HR20110178 T HR 20110178T HR P20110178 T HRP20110178 T HR P20110178T HR P20110178 T1 HRP20110178 T1 HR P20110178T1
Authority
HR
Croatia
Prior art keywords
alkyl
azoniabicyclo
octane
oxy
carbonyl
Prior art date
Application number
HR20110178T
Other languages
English (en)
Croatian (hr)
Inventor
Ford Rhonan
Mather Andrew
Mete Antonio
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20110178T1 publication Critical patent/HRP20110178T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
HR20110178T 2006-11-14 2007-11-13 Kinuklidinski derivati (hetero) arilcikloheptankarboksilne kiseline kao antagonisti muskarinskog receptora HRP20110178T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86566706P 2006-11-14 2006-11-14
US86938406P 2006-12-11 2006-12-11
PCT/GB2007/004350 WO2008059245A1 (en) 2006-11-14 2007-11-13 Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20110178T1 true HRP20110178T1 (hr) 2011-04-30

Family

ID=39048793

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110178T HRP20110178T1 (hr) 2006-11-14 2007-11-13 Kinuklidinski derivati (hetero) arilcikloheptankarboksilne kiseline kao antagonisti muskarinskog receptora

Country Status (29)

Country Link
US (2) US8207193B2 (cg-RX-API-DMAC7.html)
EP (2) EP2256117A1 (cg-RX-API-DMAC7.html)
JP (1) JP4904402B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090078828A (cg-RX-API-DMAC7.html)
AR (1) AR063804A1 (cg-RX-API-DMAC7.html)
AT (1) ATE496916T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007321019B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718750A2 (cg-RX-API-DMAC7.html)
CA (1) CA2669326A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003260A1 (cg-RX-API-DMAC7.html)
CO (1) CO6160312A2 (cg-RX-API-DMAC7.html)
CY (1) CY1111351T1 (cg-RX-API-DMAC7.html)
DE (1) DE602007012300D1 (cg-RX-API-DMAC7.html)
DK (1) DK2094694T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP099338A (cg-RX-API-DMAC7.html)
HR (1) HRP20110178T1 (cg-RX-API-DMAC7.html)
IL (1) IL198314A (cg-RX-API-DMAC7.html)
MX (1) MX2009004780A (cg-RX-API-DMAC7.html)
MY (1) MY148392A (cg-RX-API-DMAC7.html)
NO (1) NO20092224L (cg-RX-API-DMAC7.html)
NZ (1) NZ576679A (cg-RX-API-DMAC7.html)
PE (1) PE20081164A1 (cg-RX-API-DMAC7.html)
PL (1) PL2094694T3 (cg-RX-API-DMAC7.html)
PT (1) PT2094694E (cg-RX-API-DMAC7.html)
RS (1) RS51650B (cg-RX-API-DMAC7.html)
RU (1) RU2456286C2 (cg-RX-API-DMAC7.html)
SA (1) SA07280616B1 (cg-RX-API-DMAC7.html)
TW (1) TW200825084A (cg-RX-API-DMAC7.html)
WO (1) WO2008059245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011173A2 (en) * 2006-07-21 2008-01-24 Mars, Incorporated Improvement of arginase levels/activity
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
BRPI0822693A2 (pt) 2008-05-13 2015-07-07 Astrazeneca Ab Derivados de quinuclidina como antagonistas do receptor muscarínico m3
BRPI0912657A2 (pt) * 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
MX2010013416A (es) * 2008-06-20 2010-12-21 Astrazeneca Ab Composicion farmaceutica que comprende un compuesto de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-ilo para la modulacion de la actividad del adrenorreceptor beta 2.
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
DK2433124T3 (en) * 2009-05-19 2017-06-19 Vivia Biotech Sl PROCEDURES FOR PROVIDING PERSONALIZED MEDICAL EX VIVO TESTS FOR HEMATOLOGICAL NEOPLASMS
ES2545812T3 (es) * 2010-06-22 2015-09-16 Chiesi Farmaceutici S.P.A. Derivados aminoéster de alcaloides y composición medicinal de estos
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
US10092646B2 (en) 2012-04-30 2018-10-09 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) * 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (cg-RX-API-DMAC7.html) * 1942-12-16
DE2104179C3 (de) 1971-01-29 1980-10-02 Knoll Ag, 6700 Ludwigshafen exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
FR2155927A1 (en) 1971-10-15 1973-05-25 Synthelabo 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
FR2168881A1 (en) 1972-01-25 1973-09-07 Synthelabo Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics
FR2208649A1 (en) 1972-12-01 1974-06-28 Synthelabo 1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IL77458A (en) 1985-01-14 1990-07-26 Eisai Co Ltd Cephem derivatives,their production and antibacterial compositions containing them and certain novel intermediates therefor
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
JPH05507942A (ja) 1991-03-07 1993-11-11 ジー．ディー．サール　アンド　カンパニー 新規セロトニン作動性剤としての新規なｍｅｓｏ―アザ環式芳香族酸アミド化合物およびエステル化合物
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
PL331384A1 (en) 1996-07-29 1999-07-05 Pharmacia & Upjohn Ab Aryl cycloalkane carboxylic esters, their application, pharmaceutic compositions and method of obtaining them
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
AU745331B2 (en) 1996-11-11 2002-03-21 Meda Pharma Gmbh & Co. Kg Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
KR100869722B1 (ko) * 2000-12-22 2008-11-21 알미랄 에이쥐 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용
MXPA03005862A (es) 2000-12-28 2005-09-08 Almirall Prodesfarma Ag Derivados de quinuclidina novedosos y composiciones medicinales que los contienen.
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
EP1383730A2 (en) 2001-04-03 2004-01-28 Aryx Therapeutics Anticholinergic compounds and methods of use
NZ528888A (en) 2001-04-30 2005-10-28 Glaxo Group Ltd Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
PE20050231A1 (es) 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
AU2004285592B2 (en) 2003-11-03 2010-02-18 Norton Healthcare, Ltd. Soft steroid compositions for use in dry powder inhalers
WO2006025324A1 (ja) 2004-08-30 2006-03-09 Ono Pharmaceutical Co., Ltd. トロパン化合物およびそれらを有効成分として含有する医薬組成物
US20090105221A1 (en) 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
AU2005300150A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
TW200722418A (en) 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds
CN101233107A (zh) 2005-08-01 2008-07-30 阿斯利康(瑞典)有限公司 作为趋化因子受体调节剂用于治疗呼吸系统疾病的新哌啶衍生物
TW200738635A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
US20090182033A1 (en) 2005-12-16 2009-07-16 Argenta Discovery Ltd. Cyclic Amine Derivatives and Their Uses
US20090233965A1 (en) 2006-04-24 2009-09-17 Astrazeneca Ab Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder
KR20090030347A (ko) 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008023157A1 (en) 2006-08-21 2008-02-28 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008059239A1 (en) 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
KR20090094460A (ko) 2006-12-19 2009-09-07 아스트라제네카 아베 무스카린 수용체 길항제로서 퀴누클리디놀 유도체
WO2008075006A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
WO2008096094A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
JP5373634B2 (ja) 2007-02-07 2013-12-18 パルメイゲン・セラピューティクス・（シナジー）・リミテッド ムスカリンｍ３アンタゴニストのナパジシル酸塩
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702382D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
GB0702414D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
BRPI0807913A2 (pt) 2007-02-15 2014-06-17 Argenta Discovery Ltd Derivado heterocíclicos como receptores muscarínicos m3
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
WO2008149053A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Ltd. Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
NZ586872A (en) 2008-02-06 2012-03-30 Astrazeneca Ab Spirocyclic amide compounds
WO2009098453A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
WO2009098455A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
GB0808707D0 (en) 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
BRPI0822693A2 (pt) * 2008-05-13 2015-07-07 Astrazeneca Ab Derivados de quinuclidina como antagonistas do receptor muscarínico m3
BRPI0912657A2 (pt) 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
GB0808709D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
GB0811099D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
WO2009153536A1 (en) 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
GB0811100D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2010018352A1 (en) 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
BRPI0917978A2 (pt) 2008-08-12 2015-11-17 Astrazeneca Ab sal de 2-hidróxi-etanossulfonato
GB0814729D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Also Published As

Publication number Publication date
EP2256117A1 (en) 2010-12-01
BRPI0718750A2 (pt) 2013-12-03
DK2094694T3 (da) 2011-04-04
WO2008059245A1 (en) 2008-05-22
JP4904402B2 (ja) 2012-03-28
AR063804A1 (es) 2009-02-18
CL2007003260A1 (es) 2008-05-23
PT2094694E (pt) 2011-03-17
NO20092224L (no) 2009-06-22
SA07280616B1 (ar) 2010-11-22
PE20081164A1 (es) 2008-10-31
PL2094694T3 (pl) 2011-05-31
RU2009115829A (ru) 2010-12-20
US8207193B2 (en) 2012-06-26
RS51650B (sr) 2011-10-31
MX2009004780A (es) 2009-05-21
ECSP099338A (es) 2009-06-30
NZ576679A (en) 2011-04-29
IL198314A (en) 2013-06-27
US20130005695A1 (en) 2013-01-03
TW200825084A (en) 2008-06-16
KR20090078828A (ko) 2009-07-20
AU2007321019B2 (en) 2011-04-21
DE602007012300D1 (de) 2011-03-10
EP2094694A1 (en) 2009-09-02
MY148392A (en) 2013-04-15
RU2456286C2 (ru) 2012-07-20
CO6160312A2 (es) 2010-05-20
IL198314A0 (en) 2010-02-17
US20100029713A1 (en) 2010-02-04
HK1134091A1 (en) 2010-04-16
ATE496916T1 (de) 2011-02-15
CY1111351T1 (el) 2015-08-05
AU2007321019A1 (en) 2008-05-22
EP2094694B1 (en) 2011-01-26
JP2010509391A (ja) 2010-03-25
CA2669326A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
HRP20110178T1 (hr) Kinuklidinski derivati (hetero) arilcikloheptankarboksilne kiseline kao antagonisti muskarinskog receptora
JP2010509391A5 (cg-RX-API-DMAC7.html)
RU2009120229A (ru) Производные хинуклидинола в качестве антагонистов мускариновых рецепторов
AU2005216904B2 (en) Modulation of inflammatory and metastatic processes
RU2399620C2 (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
ES2242653T3 (es) Nuevo uso y nuevos derivados de n-azabiciclo-amida.
ES2787704T3 (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis B
JP2012525431A5 (cg-RX-API-DMAC7.html)
ZA200602174B (en) Bicyclic[3.1.0]derivatives as glycine transporter inhibitors
JP2010513434A5 (cg-RX-API-DMAC7.html)
JP2005533826A5 (cg-RX-API-DMAC7.html)
JP2003500404A5 (cg-RX-API-DMAC7.html)
HRP20100153T1 (hr) Antagonisti kemokin receptora
HRP20171748T1 (hr) 6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba
JP2007513915A5 (cg-RX-API-DMAC7.html)
RU2006126663A (ru) Полициклические средства для лечения респираторно-синцитиальных вирусных инфекций
ME02373B (me) Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze
BR0110240A (pt) Composto, processo para a preparação de um composto, processo para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
JPWO2001040227A1 (ja) トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
CA2564742A1 (en) Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
SI9300513B (sl) Kvarterni bazični amidi, postopek za njihovo pripravo in farmacevtski sestavki, v katerih so prisotni
JP2010514721A5 (cg-RX-API-DMAC7.html)
HRP20100522T1 (hr) Piridin karboksamidi kao inhibitori 11-beta-hsd1
JP2010502716A (ja) インターロイキン１受容体関連キナーゼの調節物質
JP2008525502A5 (cg-RX-API-DMAC7.html)